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Background: In anal cancer, there are no markers nor other laboratory indexes that can
predict prognosis and guide clinical practice for patients treated with concurrent chemo
radiation. In this study, we retrospectively investigated the inﬂuence of immune inﬂamma-
tion indicators on treatment outcome of anal cancer patients undergoing concurrent chemo
radiotherapy.
Methods: All patients had a histologically proven diagnosis of squamous cell carcinoma of
the anal canal/margin treated with chemoradiotherapy according to the Nigro’s regimen.
Impact on prognosis of pre-treatment systemic index of inﬂammation (SII) (platelet x
neutrophil/lymphocyte), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio
(PLR) were analyzed.
Results: A total of 161 consecutive patients were available for the analysis. Response to
treatment was the single most important factor for progression-free survival (PFS) and overall
survival (OS). At univariate analysis, higher SII level was signiﬁcantly correlated to lower
PFS (p<0.01) and OS (p=0.046). NLR level was signiﬁcantly correlated to PFS (p=0.05), but
not to OS (p=0.06). PLR level signiﬁcantly affected both PFS (p<0.01) and OS (p=0.02). On
multivariate analysis pre-treatment, SII level was signiﬁcantly correlated to PFS (p=0.0079),
but not to OS (p=0.15). We developed and externally validated on a cohort of 147 patients
a logistic nomogram using SII, nodal status and pre-treatment Hb levels. Results showed
a good predictive ability with C-index of 0.74. An online available calculator has also been
developed.
Conclusion: The low cost and easy proﬁle in terms of determination and reproducibility
make SII a promising tool for prognostic assessment in this oncological setting.
Keywords: NLR, PLR, SII, anal cancer, prognostic factors
Introduction
Anal cancer is an uncommon cancer, with an incidence of 1–2 new cases/100,000
per year worldwide.1 Etiologically, 80–90% of squamous cell carcinoma (SCC) is
associated with high-risk human papillomavirus (HPV) type infections, in particu-
lar, HPV 16.2,3 In developed countries, the incidence of anal SCC is increasing by
1–3% per year, parallel to a higher incidence of HPV infection.4
In the past, the standard of care for invasive anal carcinoma was represented by
abdominoperineal resection (APR); local recurrence rates were high and the
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morbidity related to permanent colostomy was
considerable.5 In 1974, Nigro and colleagues described
complete tumor regression in some patients treated with
preoperative 5-ﬂuorouracil (5-FU)-based chemotherapy in
combination with radiotherapy (CT-RT).6 Successively,
randomized trials evaluating the efﬁcacy and safety of CT-
RT supported the use of this combined modality
approach.7,8
Nowadays, the standard of treatment for localized dis-
ease is still represented by RT in combination to CT with
5-FU and mitomycin, with a 5-year overall survival (OS)
rate of 60%.8 Abdominoperineal resection and colostomy
are limited to patients with locally biopsy-proven progres-
sive or recurrent disease after CT-RT.9 The standard of
care in metastatic disease is combined Cisplatin and 5-FU.
The 5-year survival rate is 15%, with a median survival
time of 12 months.10,11 Outcomes for patients with anal
cancer depend on tumor characteristics, clinical stage at
presentation, patient-related factors and laboratory para-
meters; in particular, the European Organization for
Research and Treatment of Cancer trial 22861 (EORTC
22861) has demonstrated that skin ulceration, nodal invol-
vement and male gender were the most important prog-
nostic factors for local control and survival.8
In anal cancer, however, no markers or other laboratory
indexes are validated and used in clinical practice for
predicting the prognosis and appropriately guiding the
clinical practice. In the last few years, research interest
has grown on the correlation between cancer and inﬂam-
mation, which is now recognized as a hallmark of cancer
development and progression.12 The association between
clinical outcomes and local and systemic inﬂammation has
been demonstrated in different malignancies. In particular,
neutrophils, lymphocytes, platelets and acute-phase pro-
teins (such as C-reactive protein) have been evaluated in
various cancer types, and high levels of these biomarkers
have been proven to predict for poorer prognosis and
response to treatment.13–17
Recently, Martin et al.18 and the ACT I19 trial have
showed that in SCC a higher peripheral leukocytosis was
associated with a poor outcome in patients treated with
CT-RT. Moreover, Martin et al. demonstrated an inverse
correlation between leukocytosis and intratumoral CD8+
in this setting of patients.
Several inﬂammation and immune-based prognostic
scores, such as lymphocyte count, neutrophil-lymphocyte
ratio (NLR) and platelet-lymphocyte ratio (PLR), have
been developed to predict survival and recurrence in
cancer patients.20,21 For SCC, Toh et al.22 demonstrated
that pretreatment NLR may be a predictor of outcome in
this setting of patients.
Another interesting parameter is represented by the
systemic index of inﬂammation (SII) given by the combi-
nation of platelet count and NLR. Since SII is determined
by three different types of inﬂammatory cells, it can be
regarded as a reliable surrogate for systemic inﬂammatory
response mirroring the balance between tumor and host.
The prognostic role of SII has been explored in several
tumors and it has been demonstrated to be strongly asso-
ciated to poor outcome when it is increased.16,23
In this study, we retrospectively investigated the inﬂu-
ence of immune inﬂammation indicators on the treatment
outcome of anal cancer patients undergoing concurrent
CT-RT.
Patients and methods
For the present study, all medical records were retrieved
from the databases of 3 different Institutions.
Data were entered into electronic data ﬁles by coinvestiga-
tors from each center and checked at the data management
center for missing information and internal consistency.
Written informed consent for treatment was obtained from all
patients. The Ethical Review Board of C.E.ROM (Comitato
Etico della ROMagna) approved the present study. The study
was carried out in accordance with the Declaration of Helsinki
under good clinical practice conditions.
All patients had a histologically conﬁrmed diagnosis of
SSC located in either the anal canal or margin. We
included patients with clinical stage T1-T4, N0-N3, M0
(tumor stage was deﬁned following the indications of the
American Joint Committee on Cancer, 2002 version).
Patients with clinical T1N0 tumors of the anal margin
were excluded because they were treated with local
excision.
All patients were treated with CT-RT according to the
Nigro’s regimen between 2005 and 2016.
CT consisted of 5-FU (1,000 mg/m2/day) given as
continuous infusion for 96 hrs (days 1–5 and 29–33)
combined with mitomycin C (10 mg/m2) given as bolus
(days 1 and 29). Mitomycin C was capped at 20 mg
maximum dose. A total of 2 concurrent cycles were
planned for each patient.
Patients were treated with two different RT
approaches. In the ﬁrst institution, patients were sub-
mitted to a simultaneous integrated boost (SIB) RT
approach and dose prescription was set according to
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the RTOG 0529 indications based on clinical stage at
presentation.20,24,25 Patients with cT2N0 disease were
given 50.4 Gy in 28 fractions (1.8 Gy daily) for the
primary anal tumor, while 42 Gy in 28 fractions (1.5
Gy daily) for the elective nodal volume. Patients pre-
senting with cT3-T4/N0-N3 disease were prescribed 54
Gy in 30 fractions (1.8 Gy daily) to the gross tumor
volume, while 50.4 Gy in 30 fractions (1.68 Gy daily)
or 54 Gy in 30 fractions (1.8 Gy daily) to the gross
nodal disease if sized <3 cm or >3 cm, respectively.
Elective nodal volume was prescribed 45 Gy in 30
fractions (1.5 Gy daily).26,27 Details and results of
this treatment strategy have been previously
described.23,24,27 In the second and third institution,
the patients were given a ﬁrst sequence of RT 45 Gy
in 25 fractions (1.8 Gy daily) delivered over 5 weeks
to the macroscopic primary and nodal tumor and pro-
phylactic volumes (pelvic and inguinal nodes, ischio-
anal fossa and mesorectum). In the second sequence,
a further dose of 9–14.4 Gy in 5–8 fractions was
delivered sequentially to the macroscopic disease up
to a total nominal dose of 54–59.4 Gy.
Pre-treatment evaluation included: chest, abdomen and
pelvis computed tomography scan and a magnetic reso-
nance imaging of the pelvic region.
Response to treatment was assessed at 2 time-points,
namely at 6 weeks and at 3 months of CT-RT.
Validation cohort consisted of 147 patients and was
obtained by three other institutions in France and Italy.
Treatment speciﬁcs for each institution were similar to
those previously reported, with same regimens of che-
motherapy. The radiotherapy approach used was
a sequential boost strategy similar to the one used in
the second and third institution.
Statistical analysis
Primary endpoints were progression-free survival (PFS)
and OS. PFS was deﬁned as the time from start of treat-
ment to progression (both clinical or radiological), or
death from any cause. OS was deﬁned as time from start
of treatment to death from any cause. Response to treat-
ment was assessed using the RECIST criteria. The time-to-
event functions were estimated using Kaplan-Meier survi-
val curves, and differences between covariates were
addressed with the log-rank test. Univariate and multivari-
ate Cox proportional-hazard models were also used to
estimate the hazard ratios (HR) and the associated 95%
conﬁdence interval (95% CI). We used both the forward
and backward approach to create multivariable models.
Wald test and likelihood ratio tests for the case of nested
models were used to assess signiﬁcance of both single
covariates and the entire models. Proportional hazard
assumption was tested with visual inspection of log–log
survival curves, plotted scaled Schoenfeld residuals and
global Kolmogorov-Smirnov test. Collinearity among
independent variables was investigated with ANOVA and
Fisher’s exact test of difference between means.
Investigated variables included age, gender, tumor and
nodal stage, response to treatment, overall treatment dura-
tion, HIV positivity, grading, total delivered dose of RT.
Tumor and nodal stage were recorded using the AJCC
cancer staging 7h edition. Response was evaluated using
the RECIST criteria. Absolute values of pre-treatment
platelets, lymphocytes and neutrophils were assessed 6
days before the start of treatment. NLR and PLR were
both obtained by dividing the number of neutrophils or
platelets by the number of lymphocytes. SII was obtained
by using the formula: (neutrophils × platelets)/lympho-
cytes. ROC curves were constructed to assess the best cut-
off point for categorization of continuous variables.
Considering the remarkable impact of response to CT-RT
on both PFS and OS and the poor prognosis of patients
who did not respond to treatment, we created a predictive
model for progressive disease (PD), in the attempt to
identify those patients with a worse prognosis. We used
unconstrained logistic regression, considering stabilization
or progression (SD or PD) as 1, and complete and partial
responses (CR or PR) as 0. First, all covariates were tested
in univariate models, and then a multivariate model was
developed, using both the forward and backward method.
Collinearity was assessed as above. Decision on which
covariate to include in the ﬁnal model was made taking
into account their statistical signiﬁcance, the magnitude of
change induced in the logit induced and their clinical
plausibility. A nomogram was ﬁnally developed based on
the ﬁnal multivariate logistic model. Considering the wide
variability in the SII index, a natural logarithmic transfor-
mation was applied to this variable. Predicted probabilities
were tested against the observed probabilities in the vali-
dation set. Somer’s D, Harrell C index, Spiegelhalter Z-test
and Brier score were used to evaluate the discrimination of
the model. 95% conﬁdence intervals (95% CI) of the
C index were calculated with bootstrap. Calibration plot
was assessed visually. All analyses were performed with
“rms”, “pROC” and “survival” packages of R software
environment (https://www.r-project.org/).
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Results
A total of 161 consecutive patients with anal cancer were
available for the Development Set (DS) and 147 for the
Validation Set (VS).
Patients and treatment characteristics are shown in
Tables 1 and S1, respectively. After a median follow-up
of 27 months (range: 1–30) in the DS, we observed 3-year
PFS and OS of 67.5% (95% CI:64.2–80.5%) and 83.1%
(95% CI:76.4–90.5%), respectively. Five-year PFS and OS
were 64% (95% CI:64.2–80.5%) and 76.1% (95%
CI:67.3–86.0%) (Figure S1). PFS and OS in the VS were
similar but with slightly better results (Figure S2). 3-year
PFS and OS were, respectively, 86.1% (95% CI:
80.3–92.3%) and 89.1% (95% CI:83.9–94.7%). Five-year
PFS and OS were 80.2% (95% CI: 72.6–88.6%) and
79.5% (95% CI:71.5–88.5%).
Table S2 shows the results of the univariate analyses
presented in the previous study.28
Considering SII, PLR and NLR as continuous vari-
ables, a higher baseline value of these indexes was asso-
ciated to a higher risk of treatment failure and death
(Figure 1). A higher SII level was signiﬁcantly correlated
to lower PFS (HR:2.13; 95% CI:1.69–2.59%; p<0.01) and
OS (HR:1.70; 95% CI:1.13–2.27%; p=0.046). NLR level
was signiﬁcantly correlated to PFS (HR:1.13; 95%
CI:1.01–1.26%; p=0.05), but not to OS (HR: 1.15; 95%
CI:1.0–1.315; p=0.06). PLR level signiﬁcantly affected
both PFS (HR:1.44; 95% CI:1.20–1.68%; p<0.01) and
OS (HR:1.43; 95% CI:1.13–1.73%; p=0.02).
Considering platelet, neutrophil and lymphocyte
counts, data showed that only platelet values could predict
for PFS (HR:1.71; 95% CI:1.22–2.38%). None was pre-
dictive for OS.
On multivariate analysis, response to treatment
maintained a signiﬁcant correlation to PFS (less than
PR vs CR; HR:30.03; 95% CI:7.97–113.2%; p<0.0001)
Table 1 Patient characteristics
Variable Development set, n=161 Validation set, n=147 p-value
Age Mean 62 68.8 0.098
Range 36–83 42–91
Sex Male 26 (16.2) 35 (23.8) 0.115
Female 135 (83.8) 112 (82.2)
Pre-treatment Hb Mean 13.1 13.2 0.339
Range 7.6–16.8 8.8–17.2
T-stage T1 14 (8.7) 7 (4.7) 0.067
T2 90 (56.0) 71 (48.4)
T3 40 (24.8) 35 (23.8)
T4 15 (9.3) 27 (18.4)
NA 2 (1.2) 7 (4.7)
N-stage N0 91 (56.6) 74 (50.3) 0.012
N1 26 (16.1) 31 (21.1)
N2 34 (21.1) 19 (12.9)
N3 10 (6.2) 23 (15.7)
Global stage I 13 (8.1) 9 (6.1) 0.104
II 72 (44.7) 47 (32)
IIIA 29 (18.0) 39 (26.5)
IIIB 46 (28.6) 45 (30.6)
NA 1 (0.6) 7 (4.8)
Grade G1 12 (7.5) 32 (21.8) <0.01
G2 86 (53.4) 52(35.3)
G3 45 (27.9) 33 (22.5)
NA 18 (11.2) 30 (20.4)
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(PR vs CR HR:2.44; 95% CI:1.05–5.71%; p=0.0028)
and OS (less than PR vs CR; HR:43.82; 95%
CI:10.03–191.42%; p<0.0001) (PR vs CR:
HR:3.51;95% CI-1.01–12.18%;p=0.0492). Pre-
treatment SII level had a signiﬁcant correlation to
PFS (HR:1.57;95% CI:1.21–2.03; p=0.007), but not to
OS (HR:1.21;95% CI:0.85–1.80; p=0.15).
In the development cohort, the comparison of mean
pre-treatment SII values in patients having CR (mean:
696,542) or PR (mean: 627,892) and in those having
SD + PD (mean: 1,270,000) showed a trend for
a signiﬁcant difference. However, if the same analysis
was applied to the entire population, a signiﬁcant differ-
ence in baseline SII was present (Figure 2)
ROC analysis to identify the best cut-off point was per-
formed on the entire population. SII obtained an area under
the curve (AUC) of 0.61. Setting the cut-off point at 560,000,
patients with higher pre-treatment SII had a 5-year PFS of
73.2%, compared to 85.4% for those with lower values
(Figure 3 (left), log-rank test p-value =0.023). Five-year OS
was 65.7% for patients having SII ≥560,000, and 83.2% for
those having baseline SII <560,000 (Figure 3 (right), log-
rank test p-value=0.014).
Considering all variables potentially predictive for
response, univariate analysis showed a high risk of treatment
failure and death connected to SII values (OR:3.03; 95%
CI:2.24–3.84%), nodal involvement (OR:13.73;
95% CI:11.64–15.82%), baseline hemoglobin level
NLR 1.15 1 - 1.31
1.13 - 1.73
1.13 - 2.27
0.50 1.0 2.0 4.0
0.50 1.0 2.0 4.0
1.43
1.70
HR
Univariate analysis for overall survival Univariate analysis for progression-free survival
95% CI
PLR
Sll
NLR 1.13 1.01 - 1.26
1.20 - 1.68
1.69 - 2.57
1.44
2.13
HR 95% CI
PLR
Sll
Figure 1 Univariate analysis of progression-free survival and overall survival.
Abbreviations: NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; SII, systemic index of inﬂammation.
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Figure 2 SII value for category of response.
Abbreviation: SII, systemic index of inﬂammation.
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(OR:0.61; 95% CI:0.24–0.98%), NLR (OR:1.24; 95%
CI:1.01–1.47%) and PLR (OR:1.65; 95% CI:1.20–2.11%).
SII (OR: 2.99; 95% CI: 2.04–3.94%) and lymphnode status
(OR: 5.88; 95% CI: 3.37–8.40%) were the only predictors of
response to CT-RT in multivariate analysis.
Construction and validation of
nomograms
Based on multivariable model, a nomogram for the prediction
of a higher risk of treatment failure (non-responding to treat-
ment) was created based on SII, pre-treatment hemoglobin
values and nodal status. Speciﬁcs regarding univariate and
multivariate analyses are reported in Table S3. The graphical
representation of the nomogram is shown in Figure 4.
Probabilities predicted by the nomogram were tested against
those observed in the validation set. The nomogram discrimi-
native ability was satisfying with a C-index of 0.742
(0.596–0.951) (Figure S1). Brier score was 0.055 and the
Spiegelhalter Z-test was not signiﬁcant (p=0.726). Visual
inspection of the calibration plot showed acceptable overlap
between predicted and observed probabilities, even if there
was a slight underestimation for patients at higher risk of
nonresponse.
A calculator (ARC: Anal cancer Response Classiﬁer) has
also been developed and it is available for online consulta-
tion. The link is accessible in supplemental materials.
Discussion
In the present study, we analyzed the correlation between
baseline immune inﬂammation indicators and prognosis in
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Figure 3 Progression-free survival (left) and overall survival (right) by pre-treatment SII.
Abbreviations: NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; SII, systemic index of inﬂammation.
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Figure 4 Nomogram with predictors of response to chemoradiotherapy.
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patients with SCCA. We found that pre-treatment SII levels
had a signiﬁcant correlation to PFS, being the most important
parameter for response prediction in this setting of patients.
Standard CT-RT for radical treatment in SCCA provides
consistent results in terms of local control and survival.
However, not all patients are suitable for deﬁnitive treatment
and a subset of patientsmay have a dismal prognosis, with little
or no response to CT-RT. Our analysis showed that objective
clinical response is the most important predictor of long-term
survival and cure. Patients who do not respond to treatment
face a very poor prognosis; regardless of salvage strategies in
the attempt to identify this subset of patients, we developed
a nomogram to predict the absence of response in anal cancer
undergoing CT-RT. Nomograms are useful tools for risk pre-
diction and classiﬁcation.Although several kinds of algorithms
may be used for the same purpose, to date nomograms remain
the most powerful and widely used tool to be applied in the
clinics. One substantial advantage of nomograms is that they
are easy to understand and used by professionals with a little
statistical background. For example, a patient without metas-
tasis in the lymphnode, hemoglobin pretreatment of 13 and SII
of 12 would have a total of 48 points (metastasis in the
lymphnode = 0 points; HB =18 points and SII = 30 points).
This patient had 0.2% prediction of no response. Another
patient with metastasis in the lymphnode, HB pretreatment of
13 and SII of 12 would have a total of 86 points (metastasis in
the lymphnode = 38 points; HB = 18 points and SII = 30
points). This patient had a slightly higher probability of non-
response (2%). Conversely, a patient with metastasis in the
lymphnode, HB pretreatment of 13 and SII of 15 would have
a total of 146 points (metastasis in the lymphnode = 38 points;
HB = 18 points and SII = 90 points) and 38% prediction of no
response. In our nomogram, SII showed the greatest accuracy
in predicting response. An online available calculator (ARC:
Anal cancer ResponseClassiﬁer) has also been developed. The
link is accessible in supplemental materials.
Inﬂammation is an intrinsic feature of cancer, contributing
to its development and progression.29 SII represents the bal-
ance between protumor inﬂammatory pathway activation and
antitumor immune function. A rise in SII can be determined by
three conditions, ie, neutrophilia, lymphopenia and thrombo-
cytosis, suggesting a high inﬂammatory status and an
exhausted immune response in patients. For these reasons,
we think that patients with higher SII had a worse clinical
response to CT-RT. This could be explained by the recent
results of Martin et al. and the ACT I trial that showed that
higher peripheral leukocytosis is associatedwith poor outcome
in patients treated with CT-RT. Moreover, Martin et al.
demonstrated an inverse correlation between leukocytosis
and intratumoral CD8+. Balermpas et al.30 also proved that
high tumorHPV16 viral load, CD8+ and PD-L1 are associated
with favorable prognosis in this setting of patients. Conversely,
Zhao et al.31 andGovindarajan et al.32 highlighted the negative
impact of the expression of PD-L1 on clinical outcome. These
studies demonstrated a high level of PDL-1 expression.
According to these data, a recent study proved an encouraging
antitumor activity in patients with PD-L1-positive advanced
anal carcinoma HPV+.33
Neutrophilia can prompt secretion of vascular endothe-
lial growth factor, angiogenetic cytokine and therefore
accelerate tumor development and seeding at distant
organ sites.34,35 On the other hand, lymphopenia is asso-
ciated with a more severe level of the disease36–38 and
immune escape of tumor cells from tumor-inﬁltrating
lymphocytes.39,40
In anal cancer patients, baseline leukocytosis (deﬁned
as leukocyte >10,000/ul) and neutrophilia (deﬁned as neu-
trophil count >7,500/ul) were found to be signiﬁcantly
associated (p<0.01) to oncological outcomes [OS, PFS
and disease-free survival (DFS)], independently of tumor
and nodal stage at diagnosis.41 These 2 biomarkers were
also externally validated as independent prognostic factors
in the same group.42
This was also conﬁrmed by the study by Banerjee
et al. in which patients with leukocytosis (leucocyte
>10.000/ul) and anemia (pre-treatment Hemoglobin
level <12.5 g/dl) had poor DFS and OS.43 This is in
line with our ﬁndings, where both SII (a measure that
reﬂects leukocyte number) and anemia were found to be
predictors of response to CT-RT, which is a reliable sur-
rogate endpoint for survival.28
Several studies have shown that platelets induce circu-
lating tumor cell epithelial-mesenchymal transition and pro-
mote extravasation to metastatic sites.44 Circulating
platelets actively signal to tumor cells, via TGFβ and NF-
κB, to promote their malignant potential outside the primary
microenvironment, inducing prometastatic phenotype.44
In this context, a rise in SII represents the lack of a correct
balance of immune control in the tumor itself: this could
explain the worse outcomes that we reported in this study.
Toh et al22 proved that pretreatment NLR could be
a predictor of outcome in these patients, although our
results showed that SII was a better predictor than NLR.
Based on our nomograms, for patients with higher risk of
no response to CT-RT, CT-RT response should be evaluated
before the 56th week, and biopsies should be performed
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more frequently for response monitoring. Furthermore, these
patients should undergo treatment according to dose escala-
tion protocols or boost with brachytherapy.
The main limitations to this work are its retrospective
nature and a relatively short follow-up time. Although we
considered many known prognostic factors (eg, gender and
age), we cannot completely rule out the possibility of selection
bias or bias from other confounders. It is also possible that
a longer follow-up would have yielded different results.
However, our ﬁndings are statistically signiﬁcant and in line
with previous publications on other cancer types. Another
limitation are the different time points when complete response
was assessed, as they varied across participating centers.
The literature is consistent in saying that systemic
inﬂammation indexes are related to prognosis and
response to treatment: our results conﬁrmed SII as
a strong and independent prognostic factor for both
response and PFS, which could be helpful in identifying
patients most likely not to beneﬁt from CT-RT for whom
other treatment strategies should be timely evaluated.45
In conclusion, the low cost and easy proﬁle in terms of
determination and reproducibility make SII a promising
tool for prognostic assessment in this oncological setting.
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Table S1 Treatment characteristics
Variable N (%)
SIB 96 (59.6)
PTV dose-tumor (Gy)
54 Gy/30 fractions 58 (60.4)
50.4 Gy/28 fractions 38 (39.6)
PTV dose-positive nodes (Gy)
54 Gy/30 fractions 8 (21.6)
50.4 Gy/30 fractions 29 (78.4)
PTV dose-negative nodes (Gy)
45 Gy/30 fractions 58 (60.4)
42 Gy/30 fractions 38 (39.6)
Sequential boost 65 (40.4)
First-phase PTV
45 Gy/25 fractions 65 (100)
Sequential boost PTV
Yes 63 (96.9)
9 Gy 40 (61.5)
14.4 Gy 23 (35.4)
No 2 (3.1)
Chemotherapy
5-FU + MMC 158 (98.1)
No 3 (1.9)
Abbreviations: 5-FU, 5-ﬂuorouracil; MMC, mitomycin; SIB, simultaneous integrated boost, PTV, planning target volume.
Table S2 Results of univariate analysis of the previous study
PFS OS
HR (95% CI) P-value HR (95% CI) P-value
SD+PD vs CR 41.8 40.9–42.7 <0.0001 53.3 52.1–54.3 <0.0001
PR vs CR 2.96 1.35–6.54 0.0071 2.45 0.82–7.31 0.1
Hb as a continuous variable 0.57 0.39–0.85 0.049 0.53 0.29–0.96 0.047
Abbreviations: CI, conﬁdence interval; CR, complete response; Hb, hemoglobin; HR, hazard ratio; OS, overall survival; PD, progressive disease; PFS, progression-free
survival; PR, partial response; SD, stable disease.
Table S3 Results of univariate and multivariate logistic model for prediction of nonresponse
Variable Univariate model Multivariate model
OR 95% CI OR 95% CI
SII 3.03 2.24–3.84 2.99 2.04–3.94
N+ vs N– 13.73 11.64–15.82 5.88 3.37–8.40
Pre-treatment Hb (g/dL) 0.61 0.24–0.98 n.s. n.s.
Pre-treatment NLR 1.24 1.01–1.47 n.s. n.s.
Pre-treatment PLR 1.65 1.20–2.11 n.s. n.s.
Abbreviations: SII, systemic index of inﬂammation; N, lymph node status; Hb, hemoglobin; NLR, neutrophils to lymphocyte ratio; n.s., not signiﬁcant; PLR, platelets to
lymphocyte ratio.
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